Clinical Trials Logo

Respiratory Insufficiency clinical trials

View clinical trials related to Respiratory Insufficiency.

Filter by:

NCT ID: NCT06231446 Recruiting - Clinical trials for Respiratory Failure Patients Treated With ECMO

Extracorporeal Membrane Oxygenation for Respiratory Failure Patients

Start date: October 20, 2022
Phase:
Study type: Observational

The present study is a multicentre cohort study. Respiratory failure patients treated with extracorporeal membrane oxygenation (ECMO) were enrolled. Clinical data before and during ECMO treatment were collected. Clinical data before and during ECMO treatment were collected. By this retrospective clinical data and prospective study, to observe the current status of respiratory failure patients treated with ECMO in China, analyze the clinical characteristics and prognosis of patients, and explore the clinical prevention and treatment strategies of major complications of ECMO.

NCT ID: NCT06213779 Recruiting - Clinical trials for Acute Respiratory Distress Syndrome

The Burden of Acute Respiratory Failure in Chinese ICUs: a National Cohort Study

Start date: January 2024
Phase:
Study type: Observational [Patient Registry]

We aim to prospectively assess the burden, management and therapeutic approaches and outcomes of acute respiratory failure requiring respiratory support, during the winter months in China. The purpose of this study is to provide new and current data on the disease burden of acute respiratory failure and ARDS. It will answer the following questions: - The frequency and disease burden of acute respiratory failure in China; - The incidence of ARDS based on the new global definition within this patient cohort. - The mortality of ARDS within this cohort, and how does this vary based on ARDS categories and severity. - The long-term outcomes (1-year mortality and survivor quality of life) of ARDS within this cohort. - The nature course of ARDS (different stages and severity of ARDS). - The respiratory support management strategies, such as recruitment maneuvers, prone positioning, ECCO2R, and ECMO. - The use of drugs during ICU stays, including glucocorticoid, anticoagulant, nitric oxide, sivelestat, Xuebijing, and ulinastatin. - The economical burden of acute respiratory failure within this patient cohort. - The impact of occupation, incomes and education levels on the incidence and mortality of ARDS.

NCT ID: NCT06210386 Recruiting - Clinical trials for Acute Hypoxemic Respiratory Failure

Physiology of Helmet vs. Facemask Noninvasive Ventilation

Start date: January 19, 2024
Phase: N/A
Study type: Interventional

The optimal noninvasive management of acute hypoxemic respiratory failure is debated. Helmet noninvasive ventilation may be more effective than facemask noninvasive ventilation for these patients. Putatitve benefits of helmet use are the possibility to apply significantly higher positive end-expiratory pressure without air leaks and with good patient's comfort. In this randomized crossover study, the investigators will assess the physiological effects of helmet compared to facemask noninvasive ventilation, with the latter applied with different ventilator settings (similar to or different from helmet settings).

NCT ID: NCT06204276 Recruiting - Clinical trials for Acute Hypoxemic Respiratory Failure

Asymmetrical Versus Conventional High-flow Nasal Cannula in Acute Respiratory Failure

Start date: January 20, 2024
Phase: N/A
Study type: Interventional

The goal of this randomized crossover physiological study is to evaluate the physiologic effects of asymmetrical nasal cannula and conventional nasal cannula in patients with acute respiratory failure. The main questions it aims to answer are: - Does the asymmetrical high-flow nasal cannula reduce the diaphragm and parasternal intercostal work activity of breathing measured by ultrasound compared to conventional high-flow nasal cannula? - What is the effect of the asymmetrical high-flow nasal cannula on breathing pattern, gas exchange, and hemodynamic variables compared to conventional high-flow nasal cannula? Participants will received asymmetrical high-flow nasal cannula or conventional high-flow nasal cannula at a flow rate of 40 and 60 L/min in a random order.

NCT ID: NCT06203405 Recruiting - Critical Illness Clinical Trials

The Efficacy of P0.1-guided Sedation Protocol in Critically Ill Patients Receiving Invasive Mechanical Ventilation: A Randomized Controlled Trial

Start date: December 22, 2023
Phase: N/A
Study type: Interventional

This clinical trial aims to assess the efficacy of sedation protocol targeting optimal respiratory drive using P0.1 and arousal level compared with conventional sedation strategy (targeting arousal level alone) in patients requiring mechanical ventilation in the medical intensive care unit.

NCT ID: NCT06202144 Recruiting - Clinical trials for Acute Hypoxic Respiratory Failure

Personalized Noninvasive Support

Start date: January 12, 2024
Phase: N/A
Study type: Interventional

The optimal noninvasive respiratory support for acute hypoxemic respiratory failure is debated. Recent preliminary data indicate that both pressure-support noninvasive ventilation (NIV) and continuous-positive airway pressure (CPAP) may be of benefit. While often applied interchangeably in clinical practice, NIV and CPAP have different effects on the inspiratory effort, which is the major determinant of self-inflicted lung injury. Also, inspiratory effort widely varies among individuals. The purpose of this study is to assess the physiological effects of a noninvasive respiratory support approach guided by inspiratory effort, as compared to CPAP and NIV, in patients with moderate-to-severe acute hypoxemic respiratory failure.

NCT ID: NCT06179485 Recruiting - Clinical trials for Post-Traumatic Stress Disorder

Effect of Ketamine and Etomidate During RSI on Long Term Outcomes

RSI-LTO
Start date: April 6, 2022
Phase:
Study type: Observational

The RSI-LTO study collects long-term outcomes from the RSI trial (NCT05277896). One-third of adults who are intubated in the ED or ICU experience symptoms of posttraumatic stress disorder (PTSD). PTSD is a psychiatric disorder triggered by a "shocking, scary, or dangerous event." Critical illness, tracheal intubation, and mechanical ventilation can be traumatic and distressing events. Patients may recall the intubation procedure, the feeling of the breathing tube in their throat, or being unable to move ("paralyzed"). While on the breathing machine, patients may experience delirium, frightening hallucinations, and delusions. Patients with PTSD after critical illness can be hypervigilant, anxious, and troubled by intrusive thoughts, nightmares, and flashbacks that last months to years after critical illness and that PTSD negatively impacts patients' marriages, work, and quality of life and increases patients' risk of depression, anxiety, substance use disorder, and suicide. Ketamine may prevent PTSD symptoms by blocking the pathways in the brain's glutaminergic system that are responsible for the formation of traumatic memories In outpatients with chronic PTSD, a single dose of ketamine has been shown to reduce PTSD symptoms for up to 2 weeks. Even a modest reduction in PTSD would translate into tens of thousands of fewer cases of PTSD each year, more cases of PTSD each year than any other medical intervention evaluated to date.

NCT ID: NCT06174636 Recruiting - Respiratory Failure Clinical Trials

Lung Overdistension and Abdominal Pressure Rise

LOVE BEER
Start date: June 20, 2023
Phase: N/A
Study type: Interventional

The goal of this pilot interventional no-profit study is to evaluate airway pressure, esophageal pressure and variations in lung volume distribution with EIT in mechanically ventilated patients admitted to our UTI with respiratory failure after the application of an abdominal weight and resulting increase of intra-abdominal pressure.

NCT ID: NCT06130800 Recruiting - Sarcopenia Clinical Trials

Respiratory Sarcopenia in Institutionalized Older Adults in the Region of Murcia

Start date: May 1, 2023
Phase:
Study type: Observational [Patient Registry]

Objectives: The objectives of this study are to describe the prevalence of respiratory sarcopenia in institutionalized older adults. Methodology: A sample of approximately 120 older adults from 5 residences located in Murcia capital will participate in the study. A prospective observational study will be carried out, with one year of follow-up, with patients who have been diagnosed with respiratory sarcopenia. Sociodemographic and clinical variables, physical function (palm grip, 5STS, 4MGS), respiratory force variables (MIP and PEF) and diaphragmatic ultrasound (thickness, shortening fraction and diaphragmatic excursion) will be measured. Descriptive statistics, univariate and multivariate logistic regression models, Cox proportional hazards model and KaplanMeier curves will be used to analyze the data from the longitudinal study.

NCT ID: NCT06123143 Recruiting - Clinical trials for Neonatal Respiratory Failure

Flow and Grow - The Ideal Time to Wean CPAP Off In Extremely Low Birth Weight Infants

Flow&Grow
Start date: November 27, 2023
Phase: N/A
Study type: Interventional

Preterm neonates born at less than 30 weeks' gestation are commonly maintained on invasive or non-invasive respiratory support to facilitate gas exchange. While non-invasive respiratory support (NIS) can be gradually reduced over time as the infant grows, most weaning strategies often lead to weaning failure. This failure is evidenced by an increase in significant events such as apneas, desaturations, and/or bradycardias, increased work of breathing, or an inability to oxygenate or ventilate, resulting in escalated respiratory support. Although the optimal approach to weaning NIS remains uncertain, neonatal units that delay Continuous Positive Airway Pressure (CPAP) weaning until 32-34 weeks corrected gestational age exhibit lower rates of chronic lung disease. Therefore, the investigators aim to compare the duration on respiratory support and oxygen exposure in infants born at less than 30 weeks' gestational age who undergo a structured weaning protocol that includes remaining on CPAP until at least 32-34 weeks corrected gestational age (CGA). The hypothesis posits that preterm infants following a structured weaning protocol, including maintaining CPAP until a specific gestational age, will demonstrate lower rates of weaning failure off CPAP (defined as requiring more support and/or experiencing increased stimulation events 72 hours after CPAP weaning) than those managed according to the medical team's discretion.